|
Market Closed -
Nasdaq
21:00:00 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6.470 USD | 0.00% |
|
-4.15% | -18.72% |
| 08-11 | DiaMedica Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026 | |
| 08-10 | DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: DiaMedica Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 124.8 | 56.55 | 142.3 | 334.1 | 568.4 | 484 | - | - |
| Change | - | -54.69% | 151.72% | 134.69% | 70.13% | -14.84% | - | - |
| Enterprise Value (EV) | 124.8 | 56.55 | 142.3 | 334.1 | 568.4 | 484 | 484 | 484 |
| Change | - | -54.69% | 151.72% | 134.69% | 70.13% | -14.84% | 0% | 0% |
| P/E | -5.74x | -3.04x | -4.73x | -9.05x | -11.4x | -7.96x | -8.01x | -6.36x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | -0.3x | - | -0.7x | -0.5x | 14.46x | -0.2x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 75.4x |
| EV / Revenue | - | - | - | - | - | - | - | 75.4x |
| EV / EBITDA | - | - | -0x | -0x | -0x | -7.88x | -7.28x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -7.52x | -6.71x | -4.61x |
| EV / FCF | - | - | - | -0x | -0x | -7.84x | -7.17x | -5.28x |
| FCF Yield | - | - | - | -9.45% | -7.15% | -12.7% | -14% | -18.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.65 | -0.52 | -0.6 | -0.6 | -0.7 | -0.8125 | -0.808 | -1.017 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 6.42 |
| EBITDA 1 | - | - | -28.81 | -38.06 | -47.83 | -61.43 | -66.45 | - |
| EBIT 1 | -17.41 | -19.07 | -28.85 | -38.12 | -47.89 | -64.35 | -72.17 | -105.1 |
| Net income 1 | -17.34 | -18.63 | -26.3 | -34.92 | -45.62 | -62.66 | -71.07 | -103.9 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 3.730 | 1.580 | 2.840 | 5.430 | 7.960 | 6.470 | 6.470 | 6.470 |
| Nbr of stocks (in thousands) | 26,439 | 26,443 | 37,954 | 42,761 | 52,077 | 53,926 | - | - |
| Announcement Date | 14/03/22 | 28/03/23 | 19/03/24 | 17/03/25 | 30/03/26 | - | - | - |
1CAD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.96x | - | - | - | 349M | |
| 19.64x | 6.93x | 13.92x | 1.51% | 66.93B | |
| 31.94x | 9.24x | 44.54x | 0.04% | 61.97B | |
| -79.21x | 15.29x | -73.77x | -.--% | 28.26B | |
| 28.46x | 6.03x | 15.64x | -.--% | 24.59B | |
| -14.63x | 5.3x | -6.66x | -.--% | 24.3B | |
| 26.45x | 4.98x | 16.56x | -.--% | 19.41B | |
| 48.28x | 17.79x | 36.09x | 0.31% | 16.77B | |
| 1225.47x | 35.26x | 769.42x | -.--% | 14.18B | |
| -15x | 3382.33x | -17.29x | -.--% | 14B | |
| Average | 126.34x | 387.02x | 88.72x | 0.21% | 27.08B | |
| Weighted average by Cap. | 73.44x | 184.88x | 49.64x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DMAC Stock
- Valuation DiaMedica Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
